Pfizer wins EU's approval for Ibrance as Novartis readies rival drug

LONDON, Nov 10 (Reuters) - U.S. drugmaker Pfizer

said on Wednesday it had won approval from the European Union

for its best-selling breast cancer drug Ibrance, making it the

first medicine of its...

Read more